<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711941</url>
  </required_header>
  <id_info>
    <org_study_id>5_25/07/2019</org_study_id>
    <nct_id>NCT04711941</nct_id>
  </id_info>
  <brief_title>A ToM Training for People With Multiple Sclerosis: an Efficacy Study.</brief_title>
  <acronym>ToM</acronym>
  <official_title>Effectiveness of a Novel Theory of Mind Training for People With Multiple Sclerosis: a Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Don Carlo Gnocchi Onlus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Don Carlo Gnocchi Onlus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Theory of Mind (ToM) is the ability to understand and attribute mental states to ourselves&#xD;
      and others. People with Multiple Sclerosis (pwMS) could present an impairment of this&#xD;
      ability, with negative consequences on their social relationships and Quality of Life (QoL).&#xD;
      We aimed to design and implement a novel ToM rehabilitation training, testing its efficacy on&#xD;
      the promotion of emotional and mental states understanding, on QoL and on the alexithymia&#xD;
      traits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reading the Mind from the Eyes (RMET)</measure>
    <time_frame>4 weeks</time_frame>
    <description>A measure of affective ToM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Strange Stories</measure>
    <time_frame>4 weeks</time_frame>
    <description>A measure of advanced ToM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Faux pas</measure>
    <time_frame>4 weeks</time_frame>
    <description>A measure of both cognitive and affective advanced ToM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>False Belief Task</measure>
    <time_frame>4 weeks</time_frame>
    <description>A measure of cognitiveToM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toronto Alexithymia Scale (TAS-20)</measure>
    <time_frame>4 weeks</time_frame>
    <description>A measure of Alexithymia traits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Quality of Life 54 questionnaire (MSQOL54)</measure>
    <time_frame>4 weeks</time_frame>
    <description>A measure of Quality of Life in Multiple Sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>4 weeks</time_frame>
    <description>A measure of global cognitive level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Brief Repeatable Battery of Neuropsychological Test (BRB-NT)</measure>
    <time_frame>4 weeks</time_frame>
    <description>A measure of cognitive functions in Multiple Sclerosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>ToM training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to comprehend and hypothesize interpretations of the emotions and social interactions, providing discussion occasions to enhance the attribution of mental states and emotions. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non mentalistic training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to provide a historical and descriptive overview of cinema movies, TV news, documentaries, newspapers, and advertising. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Rehabilitation training</intervention_name>
    <description>Rehabilitation with behavioural stimuli</description>
    <arm_group_label>Non mentalistic training</arm_group_label>
    <arm_group_label>ToM training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of Relapsing-Remitting (RR), Secondary Progressive (SP) and Primary&#xD;
             Progressive (PP) MS;&#xD;
&#xD;
          -  age ≥ 18 and ≤ 75 years;&#xD;
&#xD;
          -  years of education ≥ 5;&#xD;
&#xD;
          -  no change of pharmacological treatment in the 6 months before the enrollment;&#xD;
&#xD;
          -  no clinical relapses or use of steroid treatment during 3 months before the&#xD;
             enrollment;&#xD;
&#xD;
          -  provided informed consent for study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of nervous system disorders different from MS;&#xD;
&#xD;
          -  unstable psychiatric illness, such as psychosis or major depression;&#xD;
&#xD;
          -  severe disability with Expanded Disability Status Scale (EDSS) score &gt; 7.5;&#xD;
&#xD;
          -  severe cognitive impairment that would not enable PwMS to answer to questionnaires&#xD;
             correctly (i.e. dementia), according to the patient's medical records.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alessia d'Arma, MSc</last_name>
    <phone>+39 02 40308436</phone>
    <email>adarma@dongnocchi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Fondazione Don Carlo Gnocchi</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Mendozzi, MD</last_name>
      <email>lmendozzi@dongnocchi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>theory of mind</keyword>
  <keyword>rehabilitation</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>neurodegenerative disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

